Skip to content
Menu

MaxCyte, Inc. MXCT

Full chart Compare
Set alert

Price alert · MXCT

All alert types
1.19 USD 0.00 (+0.00%)

Regular-session close

1.18 -0.01 -0.84%

After hours · Nov 13, 4:00 PM ET

1.12 Day range 1.20
0.643 52-week range 1.81
YTD
-23.23%
1 year
-21.19%
Market cap
122.87M
Revenue (ttm)
45.60M
Profit margin
-78.37%
EPS (ttm)
-0.26
Shares out
105.48M
Forward P/E
-10.41
YTD return
-23.23%
1-year return
-21.19%
Volume
1.25M
Avg volume
980.66K
Open
1.16
Previous close
1.19
Day's range
1.12 – 1.20
52-week range
0.643 – 1.81
Beta
1.16
Analysts
Strong Buy
Price target
8.67 (+628.3%)

5D -0.12 (-9.09%)

11.201.40FriMonTueWedThu1.20

Key statistics

Enterprise value
311.73M
PEG ratio
0.00
Price / sales
9.39
Price / book
2.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
2.00%
Free cash flow
-7.75M
Total cash
153.83M
Total debt
18.32M
Return on equity
-16.00%
Short % of float
2.93%
50-day average
3.75
200-day average
4.11

Fundamental scorecard

7 of 25 checks passed on MXCT’s reported financials

Value: 2/5ValueGrowth: 1/5GrowthProfitability: 1/5ProfitabilityFinancial health: 3/5HealthDividend: 0/5Dividend

7of 25 checks passed

  • Value 2 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MXCT Revenue — quarterly 10.15M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
MXCT Net income — quarterly -4.76M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
MXCT EPS — quarterly -0.05
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

MXCT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-0.13-0.11+0.02+15.38%
Aug 6, 2024Jun 1, 2024-0.14-0.09+0.05+35.71%
Aug 6, 2024Jun 1, 2024-0.14———
May 7, 2024Mar 1, 2024-0.14-0.09+0.05+35.71%
May 7, 2024Mar 1, 2024-0.14———
Mar 12, 2024Dec 1, 2023-0.10-0.05+0.05+50.00%

Upgrades / downgrades

MXCT analyst upgrades and downgrades
DateFirmActionFromTo
Apr 23, 2024Stephens & Co.reitOverweightOverweight
Mar 13, 2024Stephens & Co.reitOverweightOverweight
Mar 13, 2024BTIGmainBuyBuy
Nov 29, 2023Craig-Halluminit—Buy
Oct 5, 2023Stephens & Co.reitOverweightOverweight
Mar 28, 2023Stephens & Co.reit—Overweight

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
maxcyte.com

News

Your note

Sign in to keep a note on MXCT — it syncs with the Stock Master app.

Insider holders

MXCT insider holders
InsiderRelationLatest transactionDateShares held
AL-WAKEEL YASIR BDirectorStock Award(Grant)Jun 10, 202421,367
BALTHROP PATRICK J SRDirectorStock Award(Grant)Jun 10, 202421,367
COLLINS CYNTHIADirectorStock Award(Grant)Oct 13, 202451,679
DOUGLAS RICHARD HDirectorStock Award(Grant)Jun 10, 2024121,367
ERCK STANLEY CDirectorSaleOct 31, 2024269,118
HEMRAJANI REKHADirectorStock Award(Grant)Jun 10, 202421,367

Institution ownership

MXCT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.03%8,488,10734.46MSep 29, 2024
Cadian Capital Management, LP7.75%8,188,94833.25MSep 29, 2024
Vanguard Group Inc5.46%5,775,26823.45MSep 29, 2024
Vitruvian Partners, LLP4.77%5,043,35620.48MSep 29, 2024
Morgan Stanley4.56%4,817,13219.56MSep 29, 2024
Millennium Management Llc3.97%4,192,86517.02MSep 29, 2024

Fund ownership

MXCT fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.79%2,952,76811.99MSep 29, 2024
iShares Russell 2000 ETF2.56%2,710,46811.00MOct 30, 2024
Vanguard Extended Market Index Fund1.57%1,658,7646.73MSep 29, 2024
Morgan Stanley Inst Fund Inc-Inception Port1.10%1,160,8454.71MSep 29, 2024
Fidelity Advisor Equity Growth Fund1.07%1,126,8214.57MOct 30, 2024
Fidelity Small Cap Index Fund1.01%1,069,1994.34MAug 30, 2024